FDA’s top gene therapy regulator is leaving his role

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (11)

• UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval TradingView · 11d ago
• Manufacturing Deficiencies Behind FDA's Oxylanthanum Carbonate Rejection PharmTech.com · 11d ago
• Unicycive Therapeutics Receives Complete Response Letter GlobeNewswire · 11d ago
• Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) Yahoo Finance · 11d ago
• US FDA declines to approve Unicycive's kidney disease drug Reuters · 11d ago
• Top FDA gene and cell therapy regulator to step down Yahoo · 11d ago
• FDA’s cell and gene therapy head steps down after 1 year BioSpace · 11d ago
• FDA’s acting director of cell and gene therapies to leave position Endpoints News · 11d ago
• Top FDA gene and cell therapy regulator to step down BioPharma Dive · 11d ago
• FDA gene therapy regulator Vijay Kumar steps down from leadership role Fierce Biotech · 11d ago
• FDA’s top gene therapy regulator is leaving his role statnews.com · 11d ago broke it first

Related trends